All Posts Tagged With: "RHHBY"

Global Investing Roundups Thursday, August 14th, 2008

Deere Misses Estimates; Genentech Rejects Roche Bid; Crude Rises on Inventory Report; China Fire & Security an Earnings Inferno; Joining Forces to Battle Insider Trading; Best Buy’s Coup; Merrill Slashes Wall St. Ratings; Ford’s European Makeover

Second Quarter GDP Release Set to Confirm or Deny U.S. Recessionary Fears

A hectic week on the economic calendar is highlighted by the initial look at second quarter gross domestic product (GDP). Remember, a recession is defined as two consecutive quarters of negative growth, so doomsayers have targeted this week’s release as confirmation of their pessimism.

Biotech Sector Could Jump 25% on Roche-Genentech Deal

Swiss drug company Roche (OTC:RHHBY) may not get its hands on San Francisco-based biotech outfit Genenetech (NYSE:DNA) as quickly as it had hoped.

Genetech has formed a special committee of independent directors to evaluate the $89-a-share acquisition offer from Roche, which already owns 56 percent of the US biotech firm.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…

While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry… and its investors.

With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.

Small-cap biotechs are cheap right now. So I’d be willing to bet the sector could jump 25% or more in the coming months. And big-cap names like Biogen (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), and Elan (NYSE:ELN) have jumped to the top of Big Pharma’s short list of buyout candidates.

If you’re thinking of dabbling in the biotech sector, Roche’s bid for Genentech just may be the buy signal you’re waiting for.

Source: The Buy Signal You’ve Waited For

Switzerland’s Roche Makes $43.7 Billion Offer for U.S. Biotech Pioneer Genentech

Roche Holding Ltd. (OTC ADR: RHHBY) yesterday (Monday) announced a $43.7 billion offer for the 44% of Genentech Inc. (DNA) it doesn’t already own.

Global Investing Roundups

Takeda Acquires Millennium for $8.8 Billion; Gas Prices Driven to Another Record High; Jobless Claims Drop; Car Sales in India Up Again; China’s Trade Deficit Narrows; 100,000 Angry Airline Passengers; Favorable Amgen Ruling; BJ’s Wholesale Club Gains on Sales Increase.

Receive These Valuable Investing Strategy Resources to Your Inbox Courtesy of Contrarian Profits

    Subscribe
We respect your privacy.
Choose any of the FREE subscription services below that you'd like to receive, enter your email address, and click 'subscribe'.
Contrarian Profits

The Daily Reckoning



Select Edition:
Penny Sleuth

Money Morning

Investor's Daily Edge

Money Morning UK

Investment U

Whiskey and Gunpowder

Taipan Daily

Offshore A-Letter

Today's Financial News

The Smart Profits Report

Casey Research